Manejo de toxicidades por inmunoterapias

Diego Prost; Gabriela Cinat

doi:10.56969/oc.v22i2.70

Autores/as

Diego Prost Instituto de Oncología Ángel H. Roffo, Buenos Aires https://orcid.org/0000-0002-4962-8611
Gabriela Cinat Instituto de Oncología Ángel H. Roffo, Buenos Aires

DOI:

https://doi.org/10.56969/oc.v22i2.70

Palabras clave:

eventos adversos, toxicidad, inmunoterapia, PD-1, CTLA-4, hipofisitis

Resumen

La inmunoterapia vino para quedarse. Partiendo desde el melanoma, fue ganando terreno en tratamiento de otros tumores más prevalentes, razón por la cual actualmente es ineludible para el personal de la salud involucrado en el cuidado de pacientes oncológicos, conocer el manejo de los eventos adversos asociados a las drogas empleadas.

Citas

Boletín oficial A.N.M.A.T. disposición 7312 octubre 2011. Bristol Myers Squibb Argentina SRL-YERVOY. En: http://www. anmat.gov.ar/boletin_anmat/octubre_2011/Dispo_7312-11.pdf; consultado el 5/2/1017.

Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23. DOI: https://doi.org/10.1056/NEJMx100063

Boletín oficial A.N.M.A.T. disposición 1935 febrero 2016. Bristol Myers Squibb Argentina SRL- OPDIVO. En: http://www. anmat.gov.ar/boletin_anmat/febrero_2016/Dispo_1935-16.pdf; consultado el 5/2/2017.

Boletín oficial A.N.M.A.T disposición 0269 enero 2016. MSD Argentina SRL KEYTRUDA. En: http://www.anmat.gov.ar/ boletin_anmat/enero_2016/Dispo_0269-16.pdf; consultado el 7/2/2017.

U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. CommonTerminology Criteria for Adverse Events (CTCAE). Version 4.03. En: http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf; consultado el 8/2/2017.

Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28: 368-76. DOI: https://doi.org/10.1093/annonc/mdw443

Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30. DOI: https://doi.org/10.1056/NEJMoa1412082

Robert C, Ribas A, Wolchok JD, et al. Anti-programmed- death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-17. DOI: https://doi.org/10.1016/S0140-6736(14)60958-2

Daud A, Ribas A, Robert C, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 2016; 34: (suppl; abstr 9503). DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.9005

Weber J, Postow M, Lao C, Schadendorf CD, Schadendorf D. Management of adverse events following treatment with anti- programmed death-1 agents. Oncologist 2016; 21: 1230-40. DOI: https://doi.org/10.1634/theoncologist.2016-0055

Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-9. DOI: https://doi.org/10.1056/NEJMoa1411087

Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 2016; 22: 6051-60. DOI: https://doi.org/10.1158/1078-0432.CCR-16-1320

Robert C, Schachter J, Long JV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32. DOI: https://doi.org/10.1056/NEJMoa1503093

Pagès C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013; 23:227-30. DOI: https://doi.org/10.1097/CMR.0b013e32835fb524

Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4: 560-75.

Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1therapy. Eur J Cancer 2016; 60: 210-25. DOI: https://doi.org/10.1016/j.ejca.2016.02.024